Research-literacy siteEducational evidence reviews only — not medical advice, not dosing guidance, not a protocol for human or animal use. Medical disclaimer.

PeptideStacks

Conflict of Interest Disclosure

PeptideStacks.co.uk discloses commercial relationships in the interest of editorial transparency. This page is the source of truth for who pays for what on this site, and what those payments do and do not influence.

Paid sponsor

PeptideBarn.co.uk is a paid sponsor of PeptideStacks.co.uk under a fixed-fee placement arrangement. Sponsor placement appears in three places on the site:

  • A sister-sites & sponsor block in the Footer, on every page.
  • A compact sister-sites & sponsor panel on the homepage.
  • A clearly-labelled Sponsor panel at the bottom of each peptide and stack page — only for unapproved-compound pages; sponsor links are deliberately suppressed on pages covering UK prescription-only or POM-adjacent medicines (e.g. Tirzepatide, Semaglutide, Retatrutide, PT-141, Tesamorelin).

Every sponsor link is labelled Sponsor, carries therel="sponsored noopener external nofollow" attribute per Google’s guidance for paid placements, and includes UTM tracking parameters so the sponsor can attribute clicks by surface.

Sister site

PeptideAuthority.co.uk is a related editorial property — long-form per-peptide research monographs. PeptideAuthority is cross-linked from the same sponsor / sister-site blocks as PeptideBarn, and from in-content references on individual evidence-review pages where the long-form monograph provides additional depth. There is no advertising fee for PeptideAuthority placements; the cross-linking is editorial recirculation between related properties.

What sponsorship does not buy

Sponsorship and sister-site relationships do not:

  • Determine which evidence grade a peptide or stack receives.
  • Determine which studies are cited or how they are characterised.
  • Soften regulatory framing, safety signalling, or anti-doping language.
  • Suppress negative findings or replication caveats from being published.
  • Influence which compounds are covered on the site.
  • Add or remove content from policy pages (editorial-policy, responsible-information-policy, medical-disclaimer, citation standards).

Evidence grades, citations, safety language and regulatory framing are decided by editors on the basis of the published literature and regulatory documents, not the commercial relationship. Where the sponsor’s catalogue contains compounds that PeptideStacks grades cautiously, that grading is unchanged by the sponsorship — and where the sponsor’s catalogue includes POM-adjacent material, sponsored placement is deliberately suppressed on the relevant pages.

POM-adjacent suppression rule

Sponsor placement is rendered conditionally on the page subject. On peptide monograph and stack pages whose subject is a UK prescription-only medicine (Tirzepatide) or a POM-adjacent compound (Semaglutide, Retatrutide, PT-141 / Bremelanotide, Tesamorelin, Melanotan II, Cerebrolysin, Thymosin α-1, GHRP-2 — i.e. the full list maintained atHIGH_REGULATORY_SENSITIVITY_PEPTIDES inlib/evidence.ts), the PeptideBarn portion of the Sponsor panel is replaced with a brief disclosure explaining the suppression and pointing readers to a registered UK prescriber for any clinical questions. PeptideAuthority links remain on those pages because that property is editorial, not vendor.

Vendor claims are not evidence

Marketing material from any peptide vendor — including the sponsor — is not treated as evidence on this site. See our citation standards for the sources we do accept.

Affiliate / referral disclosure

Outbound sponsor links may be tracked via UTM parameters. The commercial arrangement with PeptideBarn is a fixed-fee placement, not a per-click or per-conversion commission. Where a reader clicks through and makes a purchase, PeptideStacks receives no incremental revenue beyond the fixed sponsorship fee.

No relationship with regulators

PeptideStacks is independent of the MHRA, EMA, FDA, WADA, and any other regulatory or sporting body. We are not authorised to speak on their behalf and our summaries of their positions are educational only.

Future relationships

If new commercial relationships are established or existing ones change materially, this page will be updated and the change recorded in our evidence changelog.